# Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial

> **Open Intelligence Dossier** · First detected: 2026-11-21 20:40 UTC · Category: Business

## Executive Summary
Merck’s sac-TMT TROP2 antibody-drug conjugate meets its primary overall survival endpoint in a pivotal Phase 3 trial for third-line or later gastroesophageal adenocarcinoma.

## Intelligence Brief
Merck &amp; Co. announced that its investigational TROP2-targeting antibody-drug conjugate sac-TMT met the primary overall survival endpoint in the TroFuse-015 Phase 3 trial, according to coverage from OncLive, FirstWord Pharma, Endpoints News, Reuters, and Fierce Biotech. The trial enrolled patients with third-line or later gastroesophageal adenocarcinoma, a category that includes advanced stomach and esophageal cancers. Coverage states that the drug prolonged survival in this patient population, marking another Phase 3 win for Merck’s sac-TMT program in gastric cancer. The reports do not specify the magnitude of the survival benefit, the hazard ratio, median overall survival figures, or the number of patients enrolled.


OncLive framed the result as TroFuse-015 meeting its primary overall survival end point with sac-TMT in third-line or later gastroesophageal adenocarcinoma. FirstWord Pharma described sac-TMT as succeeding in Merck &amp; Co.’s pivotal gastroesophageal cancer study. Endpoints News characterized the result as another Phase 3 win for sac-TMT, this time in gastric cancer. Reuters reported that Merck’s drug prolongs survival in advanced stomach and esophageal cancers in trial. Fierce Biotech headlined that Merck’s TROP2 ADC extends survival in a pivotal gastroesophageal cancer trial.


Gastroesophageal adenocarcinoma encompasses cancers of the stomach and the gastroesophageal junction, often with limited treatment options in later lines of therapy. A TROP2-directed antibody-drug conjugate delivers cytotoxic payload directly to tumor cells expressing the TROP2 antigen. Merck’s sac-TMT is positioned within a competitive class of TROP2-targeting ADCs, though coverage does not name rival agents or compare sac-TMT’s performance against other drugs in the space. The significance of the TroFuse-015 result lies in its potential to expand treatment options for patients who have progressed through multiple prior lines of therapy.


Coverage does not state when Merck plans to submit regulatory filings based on TroFuse-015, whether the company will seek accelerated or traditional approval, or which regulatory agencies will be engaged. It also does not disclose safety data, adverse event rates, or plans for earlier-line trials. Readers should watch for Merck’s next disclosure on detailed efficacy and safety results, regulatory timelines, and any companion diagnostic strategy tied to TROP2 expression.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| OncLive | TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma | [Source Link](https://news.google.com/rss/articles/CBMi0AFBVV95cUxQN25zeHNVWXl4M1hPSkpyUWhIZXc5TEhXXzVJX1ZrWTFTcTZjSUFpb0prbzQ2ODN3U3RMMzdleGhpa2Q1ZFJNNTIySHA0Um1wRXVRMGpIWHpiV1RCazJFOHktZ2lTa0ZQZmZZWVMwQU4wdmF4MklZRU0yeWFIdkEwaGlYS3hLTmp4LVdZZnl2RFg3OEdWZlVfM1NLdWNtMC1qSkdxSFZGNlI1S0ktWm1Pd2NpbGRBbl94ZUtaVHNHbE8tRzRZeWpDY0lQRjBvOUha?oc=5) |
| FirstWord Pharma | Merck & Co.'s sac-TMT succeeds in pivotal gastroesophageal cancer study | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE1sdlM2QUFhNE80cGFXSWpyVjFEMjlTRk02S1ZwU3hGVHNleHlUYkVvYldaSDFYc0V0VXdmcU42Tjl2TkllTnBoeWxJR291RXNfRGE0?oc=5) |
| Endpoints News | Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxPRmZXSXhQajRqZGwxc2hDSHpvSm9PN0JUcXZOU3JQVjZ5U3ctWFF0Sk04UUxTVTcwUW5tWmxjVTdBUl8yNWtlRW5EMUxpQnI3dVFRX2xwUHE0aDd6M29rV1FiUGhYV3dJeDd3NWtmNklyS2NGaXp6NDMyVU9VYmRpb2VoRjZNQi1MLXN4MmpCZnA1MTdOMmtqQkRR?oc=5) |
| Reuters | Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial | [Source Link](https://news.google.com/rss/articles/CBMi2wFBVV95cUxQTW5sR0gzTllxazYxWjhyaWMzcTRITlVEazRVT1V3NEhlYVhObmowSDJ4a3R1YllBQURteDdEYVdYR0tLUHhJMVhmRHFVRThDM1BzZkhDc0VkOEU0ZWVOVjVBc1ZWSVprNXVkZ1piaDBkOEw5aGx5dFFnZjVrZnlyMWFmLVd2NEszajR5QlRON1JyZEtBZFF2ZjBOSzVkcGFpNGtuMURMVTZaaWkxN0FYaUoxdFRsVGI4SUZ5cVlHT3R5X0xEbkdvUl8za3JENmg3Wk0zU3l4UHU2STA?oc=5) |
| Fierce Biotech | Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial | [Source Link](https://news.google.com/rss/articles/CBMirgFBVV95cUxPY18wOXU4Z0tEVmVYQXpKUzY1cDNKZVdsX0ZjVHBDSWdxcnJLZ2hTX0lnTkRkWFZiaVhDc1lmZU9RWkxpNC1yZS1DdFJuVTR5TDVEVGdLaGxQTHZZZnRNdWpFQUt0MEpLMUtXLUpIeVN4NzJVU3BRZnk1ZjNYT0VEc0FzcmpXOTNjeFl2d3Q3QUFESjBPRm5LYm8yVlo4TzFOQzV6SU1udXFVSUZEdmc?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-21/merck-s-trop2-adc-extends-survival-in-pivotal-gastroesophageal-cancer-trial*
